These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32721117)

  • 1. Bone scan index can be a useful biomarker of survival outcomes in patients with metastatic castration-resistant prostate cancer treated with radium-223.
    Naito M; Ukai R; Hashimoto K
    Cancer Rep (Hoboken); 2019 Oct; 2(5):e1203. PubMed ID: 32721117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer.
    Carles J; Castellano D; Méndez-Vidal MJ; Mellado B; Saez MI; González Del Alba A; Perez-Gracia JL; Jimenez J; Suárez C; Sepúlveda JM; Manneh R; Porras I; López C; Morales-Barrera R; Arranz JÁ
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1133-e1139. PubMed ID: 30104161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Relationship Between Total Lesion Activity on
    Filippi L; Basile P; Schillaci O; Bagni O
    Cancer Biother Radiopharm; 2020 Aug; 35(6):398-403. PubMed ID: 32109140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Smith M; Parker C; Saad F; Miller K; Tombal B; Ng QS; Boegemann M; Matveev V; Piulats JM; Zucca LE; Karyakin O; Kimura G; Matsubara N; Nahas WC; Nolè F; Rosenbaum E; Heidenreich A; Kakehi Y; Zhang A; Krissel H; Teufel M; Shen J; Wagner V; Higano C
    Lancet Oncol; 2019 Mar; 20(3):408-419. PubMed ID: 30738780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of two-dimensional total bone uptake (2D-TBU) and bone scan index (BSI) extracted from active bone metastatic burden on the bone scintigraphy in patients with radium-223 treatment.
    Fukai S; Daisaki H; Umeda T; Shimada N; Terauchi T; Koizumi M
    Ann Nucl Med; 2024 Jun; 38(6):450-459. PubMed ID: 38517659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program.
    Saad F; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Nilsson S; Miller K; Wirth M; Reeves J; Seger M; Carles J; Heidenreich A
    Clin Genitourin Cancer; 2019 Oct; 17(5):348-355.e5. PubMed ID: 31311763
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Fosbøl MØ; Petersen PM; Kjaer A; Mortensen J
    J Nucl Med; 2018 Apr; 59(4):596-602. PubMed ID: 28864632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.
    Romero-Laorden N; Lorente D; de Velasco G; Lozano R; Herrera B; Puente J; López PP; Medina A; Almagro E; Gonzalez-Billalabeitia E; Villla-Guzman JC; González-Del-Alba A; Borrega P; Laínez N; Fernández-Freire A; Hernández A; Rodriguez-Vida A; Chirivella I; Fernandez-Parra E; López-Campos F; Isabel Pacheco M; Morales-Barrera R; Fernández O; Villatoro R; Luque R; Hernando S; Castellano DC; Castro E; Olmos D
    Eur Urol Oncol; 2024 Jun; 7(3):447-455. PubMed ID: 37838555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases.
    Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo Perez JM; Wagner V; Li R; Nordquist LT
    Ann Oncol; 2017 Oct; 28(10):2464-2471. PubMed ID: 28961839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
    Heidenreich A; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Carles J; Wirth M; Miller K; Reeves J; Seger M; Nilsson S; Saad F
    BMC Cancer; 2019 Jan; 19(1):12. PubMed ID: 30612558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
    Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo J; Trandafir L; Wagner V; Li R; Nordquist LT
    Prostate; 2019 Oct; 79(14):1683-1691. PubMed ID: 31442327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial Experience With Radium-223 Chloride Treatment at the Kanazawa University Hospital.
    Nakashima K; Makino T; Kadomoto S; Iwamoto H; Yaegashi H; Iijima M; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kadono Y; Matsuo S; Mizokami A
    Anticancer Res; 2019 May; 39(5):2607-2614. PubMed ID: 31092459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ra-223 and Ethinylestradiol Combination Therapy in Castration-resistant Prostate Cancer.
    Shimada T; Izumi K; Kano H; Kadomoto S; Makino T; Naito R; Iwamoto H; Yaegashi H; Kadono Y; Mizokami A
    Anticancer Res; 2022 Feb; 42(2):1065-1071. PubMed ID: 35093908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer.
    Miyoshi Y; Yoneyama S; Kawahara T; Hattori Y; Teranishi JI; Ohta JI; Takebayashi S; Yokomizo Y; Hayashi N; Uemura H
    Urol Int; 2017; 99(4):400-405. PubMed ID: 28609769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
    Hoskin P; Sartor O; O'Sullivan JM; Johannessen DC; Helle SI; Logue J; Bottomley D; Nilsson S; Vogelzang NJ; Fang F; Wahba M; Aksnes AK; Parker C
    Lancet Oncol; 2014 Nov; 15(12):1397-406. PubMed ID: 25439694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database.
    Keizman D; Fosboel MO; Reichegger H; Peer A; Rosenbaum E; Desax MC; Neiman V; Petersen PM; Mueller J; Cathomas R; Gottfried M; Dresler H; Sarid D; Mermershtain W; Rouvinov K; Mortensen J; Gillessen S; Daugaard G; Omlin A
    Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):289-293. PubMed ID: 28244493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing Radiographic Response to
    Anand A; Trägårdh E; Edenbrandt L; Beckman L; Svensson JH; Thellenberg C; Widmark A; Kindblom J; Ullén A; Bjartell A
    J Nucl Med; 2020 May; 61(5):671-675. PubMed ID: 31586004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four years of clinical experience with Radium-223 for the treatment of castration-resistant prostate cancer.
    Álvarez Pérez RM; Delgado García A; García Martínez S; Sanz Viedma S; Palacios Gerona H; Pajares Vinardel M; Jiménez-Hoyuela García JM
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(5):298-304. PubMed ID: 31362912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial.
    Kitajima K; Igeta M; Kuyama J; Kawahara T; Suga T; Otani T; Sugawara S; Kono Y; Tamaki Y; Seko-Nitta A; Ishiwata Y; Ito K; Toriihara A; Watanabe S; Hosono M; Miyake H; Yamamoto S; Narita M; Daimon T; Yamakado K
    Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1487-1498. PubMed ID: 36539508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three years' clinical practice of Radium-223 therapy in patients with symptomatic bone metastases from metastatic castrate-resistant prostate cancer: a single-centre experience.
    Gazzilli M; Durmo R; Cossalter E; Cerudelli E; Panarotto MB; Albano D; Bertagna F; Giubbini R
    Nucl Med Commun; 2020 Apr; 41(4):300-307. PubMed ID: 32049940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.